Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Our experts will work with you to develop a sustainable plan that balances efficacy and affordability
Lixisenatide: This is a GLP-1 receptor agonist developed by Sanofi, marketed as Adlyxin
Fifth, our projections did not include kidney-specific endpoints, such as the composite of major kidney disease events reported in the SOUL trial, as these were outside the scope of our analysis
Who should avoid these treatments
US$ 21.16
US$ 21.69
US$ 21.78
US$ 29.24
US$ 21.53
US$ 27.10
US$ 24.58
US$ 22.94
US$ 25.50
US$ 29.40
US$ 20.86
US$ 25.95
